Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8347-8351

  Wang, Jianghua ^a   Cai, Yi ^a   Ren, Chengxi ^a   Ittmann, Michael ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; ERG GENE; EXON; FUSION GENE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TMPRSS2 GENE;

CELL LINE, TUMOR; DINUCLEOSIDE PHOSPHATES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SERINE ENDOPEPTIDASES; VARIATION (GENETICS);

EID: 33749034498     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1966     Document Type: Article

References (16)

1. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001;1:245-50.
2. Tomlins SA, Rhodes DR, Perner SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
3. Tomlins SA, Mehra R, Rhodes DR, et al TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.
4. Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci 2004;95:626-33.
5. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
7. Wang J, Weng J, Cai Y, Penland R, Liu M, Ittmann M. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to α-methylacyl-CoA racemase. Prostate 2006;66:847-57.
8. Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 2006;66:613-24.
9. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-9.
10. Owczarek CM, Portbury KJ, Hardy MP, et al. Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 2004;324:65-77.
11. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167:528-34.
12. Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 2005; 361:13-37.
13. Kozak M. An analysis of 5′ noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15:8125-48.
14. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59: 4180-4.
15. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 2001;94:705-10.
16. Agoulnik IU, Vaid A, Bingman WE III, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65: 7959-67.